Palatin Announces 1-for-50 Reverse Stock Split

Group 1 - Palatin Technologies, Inc. announced a reverse stock split at a ratio of 1-for-50, effective on August 8, 2025, with trading on a split-adjusted basis starting August 11, 2025 [1][2] - The primary goal of the reverse stock split is to increase the per-share market price to comply with NYSE American's Listing Qualifications due to the low selling price of the company's common shares [2] - Stockholders approved the reverse stock split at a ratio of 1-for-50 to 1-for-100 during the annual meeting on July 25, 2025, with the final ratio to be determined by the Board of Directors [3] Group 2 - As of the effective time, every 50 shares of the company's common stock will be combined into one share, with cash provided for any fractional shares [4] - The par value and other terms of the common stock will remain unaffected by the reverse stock split, and the new CUSIP number for the post-split common stock will be 696077 601 [4] - Palatin is a biopharmaceutical company focused on developing first-in-class medicines targeting melanocortin receptor systems for diseases with significant unmet medical needs [5]